OBJECTIVES: To document real world management and resource use for patients with CF. METHODS: Retrospective, medical chart review in eight CF centres in UK.  A stratified random sample of charts was selected from the cohort of patients ≥6 years of age with a diagnosis of CF caused by genotypes G551D or DF508 homozygous.  The study period covered the most recent two years of complete data.  Patient and clinical characteristics, health care resource and drug usage were extracted.  Categorical variables were described as number and proportion of patients and continuous variables were summarised using descriptive statistics. RESULTS: Data for 200 patients (50% female, mean age 19.5) were reviewed, with N=63 (32%) having G551D genotype.  Severity distribution measured using FEV1% was: <40%=27, ≥40% and <70%=69 and ≥70%=96 patients respectively.  Twenty different health care professional types provided care.  Nearly all patients (N=199) had a clinic visit (mean=15.2 per patient, SD=9.1, median=13), and 23% (N=45) having an emergency visit (mean=2.4 per patient, SD=2.2, median=2).  For drug usage, IV antibiotics (73.5%, N=147), nebulised therapy (87.0%, N=174), and mucolytic treatment (74.5%, N=149) were frequently used.  Pancreatic enzyme treatment was used by 96.5% (N=193), with N=180 indicating continuous use.  N=141 patients (71%) had a hospitalization with average 3.5 hospitalizations per patient (median=2); an average patient spent 48 days in hospital during the study period.  On average, for those with a procedure, 1.8 (SD=1.4) surgical (N=55) or 7.9 (SD=5.8) diagnostic (N=200) procedures were recorded. No differences were observed between G551D and DF508 genotypes in terms of severity of disease as gauged by healthcare use. CONCLUSIONS: This study, linking both clinical and resources use information indicates that high frequency and intensity of health care resource use contributes substantially to the overall burden of CF in UK. G551D and ΔF508 genotypes appear to have similar patterns of resource utilization.